Drug Profile


Alternative Names: OPC-13013; OPC-21; Pletaal; Pletal

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer Otsuka Pharmaceutical; Pfizer
  • Class Antiplatelets; Small molecules; Tetrazoles
  • Mechanism of Action Platelet aggregation inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arterial occlusive disorders; Intermittent claudication; Stroke
  • No development reported Angina pectoris
  • Discontinued Coronary artery restenosis

Most Recent Events

  • 21 Sep 2017 No development reported - Phase-III for Angina pectoris (In the elderly, Treatment-experienced, In adults) in South Korea (PO)
  • 01 Jan 2016 Otsuka Pharmaceuticals completes the phase III STELLA_Ext trial for Vasospastic Angina in South Korea (NCT02094469)
  • 01 Sep 2015 Otsuka Pharmaceutical initiates enrolment in the CiloMecT trial in Healthy volunteers (Adjunctive therapy) in Germany (NCT02554721)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top